Lucentis

News Lucentis

• Novartis receives approval for Lucentis and launches Galvus in China

  Novartis announced that it received regulatory approval in China from the State Food and Drug Administration (SFDA) for Lucentis® (ranibizumab) to treat wet (neovascular) age-related macular degeneration (AMD), and is launching Galvus® (vildagliptin), an oral treatment for patients with type 2 diabe more

• Novartis gains positive CHMP opinion for Lucentis (ranibizumab) to treat vision loss due to macular edema secondary to RVO

  Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO). Lucentis has been shown to improve vision and vision related qu more

• Novartis therapy Lucentis recommended for approval in EU to treat patients with vision loss due to Diabetic Macular Edema

  Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis (ranibizumab) for the treatment of patients with visual impairment due to diabetic macular edema (DME). The submission was supported by data from two Novartis-funded clinical trials, more

Publications Lucentis

• Trehalose: Current use and future applications

  Abstract Trehalose, a disaccharide of glucose, has been reported to accumulate in many organisms that can withstand extended periods of inanimation. Since this discovery, the properties of trehalose have been examined extensively to understand its role and abundance in nature. The unique features more

• Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study

  Evaluation of: Tufail A, Patel PJ, Egan C et al.; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 340, c2459 (2010). The ABC trial is the first multicenter, randomized clinical trial that addresses the more

Market studies Lucentis

• China Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: 2012 is a very important year for the country as the government look to carry on their achievements following the healthcare reform in 2009. We highlight that the expansion of the National Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for pharmaceuti more

• Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion (RVO) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global RVO market. The report identifies the k more

• Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Diabetic Retinopathy (DR) therapeutics market. more

Websites Lucentis